Date: 2017-11-02
Type of information: Grant
Company: Mina Therapeutics (UK) LGC LINK (UK)
Investors: Innovate UK (UK)
Amount: £400,000
Funding type: grant
Planned used:
- The grant will support a two-year research project. In 2016 MiNA Therapeutics initiated the OUTREACH Phase I clinical study of lead program, MTL-CEBPA, in severe liver cancer. LGC LINK has developed cutting edge chemistry and linker technologies to enable the targeted delivery of RNA compounds to liver cells. If successful, the research project may enable the future discovery of liver targeted saRNA
drug candidates with distinct benefits over those currently in development including a more convenient route of administration and a broader therapeutic safety window.
- Under the terms of the collaboration MiNA will have exclusive use of the results for oligonucleotide approaches that activate gene expression. LGC LINK will have exclusive use of the results for oligonucleotide approaches that inhibit gene expression.
Others:
- • On November 2, 2017, MinaTherapeuticsand LGC LINK, an oligonucleotide synthesis reagent manufacturer, and part of the Genomics division of LGC, announced that Innovate UK has awarded the two companies a grant to develop liver targeted gene activation therapies for the treatment of liver diseases. The grant of up to approximately £400,000, with
additional funding from MiNA and LGC LINK, will support a two-year research project.
Therapeutic area: Liver diseases - Hepatic diseases
Is general: Yes
